Passage Bio Inc
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galac… Read more
Passage Bio Inc (PASG) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.156x
Based on the latest financial reports, Passage Bio Inc (PASG) has a cash flow conversion efficiency ratio of -0.156x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.85 Million) by net assets ($31.12 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Passage Bio Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Passage Bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Passage Bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Passage Bio Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
TOUAX
PA:ALTOU
|
-0.317x |
|
Dynamic Precision Industry
TWO:8928
|
-0.251x |
|
Three A Resources Bhd
KLSE:0012
|
0.049x |
|
Royal Road Minerals Limited
PINK:RRDMF
|
-0.153x |
|
BENAKAT INTEGRA (J9B.SG)
STU:J9B
|
-0.048x |
|
P-Two Industries
TWO:6158
|
0.061x |
|
SaverOne 2014 Ltd. American Depositary Shares
NASDAQ:SVRE
|
-0.914x |
|
Aligned Genetics Inc
KQ:238120
|
-0.058x |
Annual Cash Flow Conversion Efficiency for Passage Bio Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Passage Bio Inc from 2018 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $61.26 Million | $-47.96 Million | -0.783x | -11.31% |
| 2023-12-31 | $111.28 Million | $-78.26 Million | -0.703x | -19.80% |
| 2022-12-31 | $201.37 Million | $-118.21 Million | -0.587x | -47.44% |
| 2021-12-31 | $318.66 Million | $-126.88 Million | -0.398x | -50.68% |
| 2020-12-31 | $304.71 Million | $-80.52 Million | -0.264x | -15.48% |
| 2019-12-31 | $174.35 Million | $-39.90 Million | -0.229x | -115.00% |
| 2018-12-31 | $-12.17 Million | $-18.57 Million | 1.525x | -- |